secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2023-09-15T23:59:59+00:00
Accession:  0001437749-23-026058
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma FY2023 revenue down 9.8%; net loss of $34K vs prior year net income $3.8M
--------------------------------------------------------------------------------

- Q4 revenue $13.0M (-2.3% YoY); operating income $79K vs $438K; net income $40K ($0.00 EPS).
- FY2023 revenue $50.7M (-9.8%); operating income $120K vs $2.7M; net loss $34K ($0.00 EPS).
- Diluted EPS $0.00 for both Q4 and FY; prior year $0.05 and $0.12 respectively.
- Contract Manufacturing Segment contributed 95% of total revenue; two largest customers accounted for ~89%.
- Warehousing/distribution business segment grew slightly as a percentage of total revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774923026058/0001437749-23-026058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774923026058/inbp20230913_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-026058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer